New weight-loss drugs are moving beyond a single hormone pathway. Survodutide, CagriSema, and MariTide use different combinations of metabolic signals to study weight management, liver health, or less frequent treatment. Their designs are promising, but “new GLP-1” is an incomplete description of how they work.

As of November 3, 2026, these three treatments remain investigational in the United States. Published trial results and regulatory submissions are important milestones; they are not the same as FDA approval. None should be treated as an established option for losing a few cosmetic pounds or purchased as a research peptide for self-treatment.

Why combine GLP-1 with other hormone pathways?

GLP-1 is a hormone involved in the body’s response to food. Medicines that activate its receptor can affect appetite and glucose regulation. Drug developers are exploring whether adding other signals produces different or greater benefits, rather than assuming that one pathway explains all eating and metabolism.

The important terms are easier to understand when separated. An agonist activates a receptor. An antagonist blocks a receptor’s activity. Combining those actions can change a medicine’s behavior, but the biological explanation is only a starting hypothesis. Clinical studies must establish whether the overall treatment helps people and at what cost in adverse effects.

Cagrilintide illustrates why terminology matters: it is an amylin analogue, not a GLP-1 receptor agonist. The GLP-1 component of CagriSema comes from semaglutide. Calling every new metabolic drug a GLP-1 can obscure meaningful differences.

Survodutide: weight management and liver research

Survodutide activates GLP-1 and glucagon receptors. Glucagon is often introduced as a hormone that raises glucose, which makes the combination sound contradictory. Its metabolic actions are broader than that single function, and the net effect of a combined drug must be evaluated in people.

One focus is metabolic dysfunction-associated steatotic liver disease, or MASLD. This involves excess liver fat in a metabolic context. MASH is the more specific condition that includes liver inflammation and injury; fibrosis refers to scarring. These terms describe related but different findings.

In the 48-week SYNCHRONIZE-MASLD phase 3 trial, survodutide was studied in adults with obesity and at-risk MASLD. The investigators reported that 84.2% of participants receiving survodutide achieved at least a 30% relative reduction in liver fat content, compared with 24.3% receiving placebo, under the efficacy analysis.

That does not mean 84.2% were cured of liver disease. It also does not mean every treated person lost 30 percentage points of liver fat. The result describes the proportion reaching a relative reduction threshold measured using MRI. Changes in liver fat, inflammation, scarring, and long-term liver complications are distinct outcomes.

Survodutide has also been studied for obesity with type 2 diabetes. This broader program is a reason to avoid describing it as exclusively a fatty-liver treatment. Which uses could eventually be authorized depends on the evidence and regulatory review.

CagriSema: pairing amylin with semaglutide

CagriSema combines semaglutide with cagrilintide, a long-acting analogue of amylin. Amylin is involved in meal-related regulation, including satiety. The combination studies whether using both pathways improves weight management compared with either component alone.

The REDEFINE 1 phase 3 trial enrolled adults with obesity, or overweight with a related complication, without diabetes. At 68 weeks, mean weight loss under the treatment-policy analysis was 20.4% with the combination, compared with 14.9% with semaglutide, 11.5% with cagrilintide, and 3.0% with placebo.

The often-cited 22.7% figure comes from a different analysis estimating the effect under adherence to treatment. Both numbers can be informative, but they answer different statistical questions. Presenting the larger number alone can hide the impact of stopping treatment or not following the intended regimen.

A trial directly comparing CagriSema with its components provides useful evidence about that combination. It still does not show that the same benefit will occur for every patient. A result in adults without diabetes should not be applied unchanged to adults with diabetes or another clinical population.

Novo Nordisk submitted a U.S. application for weight management in December 2025. Its October 2026 update continued to describe CagriSema as investigational and not approved in the United States. An application under review is a request for authorization, not permission for routine use.

MariTide: a different GIP strategy and longer intervals

MariTide is the development name for maridebart cafraglutide. It combines GLP-1 receptor activation with GIP receptor antagonism using an antibody-peptide design. This differs from tirzepatide, which activates both GIP and GLP-1 receptors.

It is tempting to conclude that one approach must be wrong because one blocks GIP while the other activates it. Human biology is more complex than a single on-off explanation. Different molecules and combinations can have useful overall effects, and the clinical evidence matters more than a simplified diagram of one receptor.

A published 52-week phase 2 trial included an obesity cohort without diabetes and a separate cohort with type 2 diabetes. In the cohort without diabetes, mean weight loss across MariTide regimens ranged from 12.3% to 16.2% under the treatment-policy analysis, compared with 2.5% with placebo. Larger figures approaching 20% reflected an efficacy analysis under different assumptions.

The long-acting design supports research into monthly and potentially less frequent schedules. A longer interval could be convenient, but convenience alone does not establish superior effectiveness, tolerability, or safety. A longer-acting medicine also does not disappear immediately if a problem develops.

Amgen’s 2026 reports describe an ongoing phase 3 program. Until regulatory review establishes an authorized use and prescribing information, a trial’s dosing schedule should not be converted into personal treatment instructions.

Why a weight-loss leaderboard can mislead

Different trials may enroll people with different starting weights, medical conditions, or previous treatments. They may run for different lengths of time, allow different dose adjustments, and handle missing data differently. A single percentage cannot resolve all those differences.

Before comparing results, ask four practical questions:

• Who was studied? Diabetes status and other eligibility criteria can change the relevance of a result.
• How long did treatment last? Results at different time points are not directly equivalent.
• What analysis produced the number? Estimates under continued adherence differ from analyses that account for treatment changes.
• What else happened? Side effects, discontinuations, physical function, and health outcomes matter alongside weight.

Head-to-head randomized studies can provide a clearer comparison within their tested conditions. They still do not make the largest average weight change the best choice for every individual. Someone’s main priority may be another health condition, tolerability, access, or preserving daily function.

Promising results do not remove safety questions

Nausea, vomiting, diarrhea, constipation, and other gastrointestinal effects appear in trials of these therapies. Side effects can affect hydration, food intake, and whether participants continue treatment. A news story that says an event was usually mild does not mean it was trivial for every person who experienced it.

Trial eligibility also limits what is known. People with certain conditions may be excluded, and uncommon risks can be harder to detect before larger or longer studies are completed. “Works with natural hormones” does not establish that a medicine is harmless. A drug can mimic a normal signal while producing effects that require careful medical management.

The FDA’s warning about unapproved GLP-1 products distinguishes authorized medicines from products that have not undergone its review. It specifically states that cagrilintide and retatrutide cannot be used in compounding under federal law. Products labeled “research use only” should not be treated as a route around clinical development.

A seller’s claim about purity cannot establish clinical safety, correct formulation, or a suitable treatment plan. Being able to buy a vial online does not mean the product matches the medicine used in a trial.

Protect nutrition and physical function during weight treatment

Weight loss can include lean tissue as well as fat. Lean mass measurements include more than skeletal muscle, so a change on a scan should not automatically be labeled an equal amount of lost muscle. At the same time, maintaining strength and adequate nutrition deserves attention, particularly after 50.

A comprehensive plan can include suitable resistance exercise, enough protein-containing food, and monitoring whether appetite suppression makes regular eating difficult. The target should fit the individual rather than rely on a universal supplement dose or a promise that one new drug preserves all muscle.

Track practical changes such as the ability to rise from a chair, carry ordinary items, and continue planned exercise. If weight is falling while strength, energy, or food intake is deteriorating, bring that pattern to the treating clinician. A lower scale reading is not the only measure of successful care.

For a broader foundation, review health habits that matter more after 50. Medication decisions work best within an overall plan for health and function.

What to discuss with a healthcare professional now

Start with the health problem that needs treatment. Is it obesity, diabetes, liver disease, or another concern? Ask which established options are appropriate today, what outcomes to expect, and what monitoring would be required. A future candidate does not automatically justify postponing effective care.

If clinical-trial participation is of interest, ask about legitimate studies, eligibility, oversight, and the possibility of receiving a comparator or placebo. Research participation has a defined protocol; it is different from purchasing an experimental compound independently.

Survodutide, CagriSema, and MariTide show how metabolic treatment is evolving. The useful question is not simply which one loses the most weight. It is which benefits have been demonstrated, for whom, with what limitations, and whether the treatment has completed the review needed for ordinary clinical use.

Video Summary

For more evidence-based nutrition and fitness tips, subscribe to our channel: https://www.youtube.com/@Vitality-and-Wellness
Looking for extra help with your fitness goals? Check out the personalized Nutrition Program at Parkway Athletic Club: parkwayathleticclub.com/nutrition

Disclaimer: This content is for educational purposes and does not replace personalized medical advice.